Prostatic Acid Phosphatase (PAP)
Code:10012|CPT:84066|LOINC:20420-6
| Includes | Prostatic Acid Phos, Serum |
|---|
Analysis details
Methodology
- Immunochemiluminometric assay (ICMA)
Expected Turnaround Time
1 day
Special Instructions
- Do not compare or combine results from different acid phosphatase methods; cross-method values are not interchangeable.
- If monitoring over time is needed, ensure all measurements are performed with the same assay platform.
- This order is intended for a single time-point measurement and is not set up for serial monitoring.
- For longitudinal monitoring, order the dedicated serial monitoring test (number 480152).
- Do not collect or transport the specimen in an acid phosphatase transport tube.
How to use
The Prostatic Acid Phosphatase (PAP) test, also referred to as Acid Phosphatase, Prostatic, is used as an adjunctive study when evaluating patients for possible prostatic cancer and for assessing therapeutic response. For longitudinal assessment, results must be generated by the same analytical method; this order code is not configured for serial monitoring, and serial trending should be ordered under test number 480152.
Limitations
This immunochemiluminometric assay quantifies the prostatic component of acid phosphatase in serum. Analytical results are method dependent; therefore, they should not be interchanged with values obtained by other acid phosphatase procedures. If serial assessment is required, all measurements should be performed using the same assay to maintain comparability. This order code is intended for a single measurement rather than a serial monitoring protocol. For longitudinal follow-up, use the laboratory’s serial monitoring option (test number 480152). Use of an acid phosphatase transport tube is not appropriate for this testing.
| Unit | ng/mL | ||||
|---|---|---|---|---|---|
| Reference interval |
| ||||
| Indications | Adjunctive evaluation of individuals with suspected prostatic malignancy., Assessment of treatment response in patients with prostate cancer when monitoring is indicated. |
Specimen Requirements
| Specimen | Serum |
|---|---|
| Container | Gold/Tiger Top (SST, Gel Separator) |
| Volume | 0.5 mL (min 0.2 mL) |
| Storage Instructions | Frozen |
References
Killian CS, Emrich LJ, Vargas FP, et al. Relative reliability of five serially measured markers for prognosis of progression in prostate cancer. J Natl Cancer Inst. 1986 Feb;76(2):179-185. PubMed 2418245